Pfizer stops sales of injectable opioids to veterinary market

Pfizer stops sales of injectable opioids to veterinary market

Company points to manufacturing issues as cause of shortage in supply.
Aug 15, 2018
By staff

Pfizer, a human biopharmaceutical company whose products are frequently used off-label by veterinarians, halted sales of injectable opioids to the veterinary market in the second quarter of 2018, a company spokesman says. It is instead prioritizing the drugs to human hospital and surgical customers.

"Pfizer Injectables has been experiencing a production delay in the manufacturing of opioid products. Pfizer has temporarily halted sales and shipments of opioids to animal/veterinarian clinics during this time of shortage," says Steve Danehy, director of corporate affairs and global media relations for Pfizer. "We value all customers and understand the importance of these medications and regret the current need to prioritize shipments to hospital and surgical trading partners."

Danehy says the company is making efforts to restock the market in ways that are equitable, efficient and compliant, and though production of their opioid has resumed, it doesn't expect to fully recover and resume selling to the full market until the second quarter of 2019.

The FDA is aware of the manufacturing issues that Pfizer is experiencing and has been working with other companies that make agency-approved injectable opioid medications to increase their production and ease the shortage, according to an FDA statement, though it will still take time for their supply to cover the shortage in the market. Those companies are Akorn Pharmaceuticals, Fresenius Kabi USA and West-Ward Pharmaceuticals.

Boycott Pfizer

Veterinarians and our patients are being hung out to dry when it comes to effective pain control. For decades pure agonist narcotics were periodically difficult to purchase because they were supposedly produced in batches. But when you couldn't get one, you could normally switch to another effective pure agonist narcotic. Now ALL pure agonists are difficult, if not impossible, to purchase. The Trump administration's idiotic method of dealing with human narcotic abuse by decreasing production goes against basic economic principles of supply and demand. Now Pfizer has shown where they stand when it comes to the veterinary drug market. Why should we support a company that has shown blatant distain for our patients. Given a choice, I will not give business to this company and I will make sure my clients are aware of what Pfizer is doing.
Brian T. Huss, DVM, MS, DACVS